American Academy of Family Physicians
American Academy of Family Physicians sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diet, with 2 trials.
Trial Pipeline
6 total, page 1 of 1
Improving Evidence-Based Primary Care for Chronic Kidney Disease
NCT01767883
To Evaluate the Use of ASTHMA IQ in a Primary Care Setting
NCT01296477
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
NCT01641341
Evaluation of the "Americans in Motion - Healthy Interventions" Project
NCT00534482
Prescription Methods Assessment Project (PMAP)
NCT00393653
Improving Health Behaviors Through Telephone Linked Care
NCT00314197
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Therapeutic Areas
What the Pipeline for American Academy of Family Physicians Shows
According to the ClinicalTrials.gov registry, American Academy of Family Physicians is linked to 6 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting, about 0% of the sponsor's indexed portfolio, and 5 are already marked complete, representing roughly 83% of the total.
The phase mix for American Academy of Family Physicians reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for American Academy of Family Physicians is Diet with 2 linked trials, and 4 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.